Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias and reperfusion-induced arrhythmias in anesthetized rats. 1999

S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
The Second Department of Medicine, Yamanashi Medical University, Tamaho, Japan.

The antiarrhythmic effect of magnesium sulfate (Mg) as well as the hemodynamics were studied using the coronary ligation and reperfusion models in rats. In the study on coronary ligation arrhythmia, i.v. administration of Mg (0.6, 2, 6, 20 and 60 micromol) was conducted at 5 min after coronary ligation. Mg had an action to decrease the total number of premature ventricular contraction (PVC), the duration of ventricular tachycardia (VT), the frequency of VT and ventricular fibrillation (Vf) and the mortality ratio for 30 min after coronary ligation. In the 6-60 micromol groups, significant antiarrhythmic action (p < 0.01 vs. control) was attained. In the study on reperfusion arrhythmia, i.v. administration of Mg (20, 60 and 200 micromol) was conducted at 4 min after coronary ligation, and at 1 min after ligation, the coronary artery was reperfused. Mg had an action to decrease the frequency of Vf, the mortality ratio and the duration of VT and Vf and to extend the interval between the initiation of reperfusion and the occurrence of VT and Vf for 10 min after reperfusion. In the 200 micromol group, significant antiarrhythmic action (p < 0.05 vs. control) was attained. Administration of Mg decreased the heart rate and blood pressure. We concluded that Mg can control myocardial ischemia-induced and reperfusion-induced arrhythmia and that sudden cardiac death which occurs as a result of arrhythmia can be prevented.

UI MeSH Term Description Entries
D008026 Ligation Application of a ligature to tie a vessel or strangulate a part. Ligature,Ligations,Ligatures
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008278 Magnesium Sulfate A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) Magnesium Sulfate, Heptahydrate,Heptahydrate Magnesium Sulfate,Sulfate, Magnesium
D008297 Male Males
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000758 Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
February 2000, Molecular and cellular biochemistry,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
December 1989, British journal of pharmacology,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
April 2000, Journal of cardiovascular pharmacology and therapeutics,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
January 1985, Journal of cardiovascular pharmacology,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
May 1992, Journal of medicinal chemistry,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
July 1982, European journal of pharmacology,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
June 1983, European journal of pharmacology,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
April 1991, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
December 2013, Current therapeutic research, clinical and experimental,
S Komori, and B Li, and K Matsumura, and M Takusagawa, and S Sano, and I Kohno, and M Osada, and T Sawanobori, and T Ishihara, and K Umetani, and H Ijiri, and K Tamura
January 2012, EXCLI journal,
Copied contents to your clipboard!